[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 2008, 34(4) 215-217 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
���������崯;���������򵰰׳������;������о�ǵ��׿���-3
���������������
������
������
�����
PubMed
Article by
Article by
Article by

�����򵰰�����������Ѱ�������崯����Ч�۲�

������ ������ ����� ��

�㶫ҽѧԺ����ҽԺƤ���Բ��о�����������ҽ��ѧ�о���������һ�� �㶫ʡ�������Ķ����� �㶫ҽѧԺ���߽�����

ժҪ��

Ŀ�� ���۾��������򵰰�����������Ѱ�������崯���ٴ��������塣���� ���ٴ��������ֱ������ӫ�⡢�������ӫ��ȷ��Ϊ���Ѱ�������崯��12�����ߣ�ÿ�쾲�������򵰰�400 mg/kg������5�죬ÿ4��1��Ϊ1�Ƴ̡����еĻ���������ʱͣ�û����������������ʡ���� 12����10���ڿ�ʼ���������򵰰׳������1�ܺ�����ơ�4�ܺ���Ƥ�ʼ���������30%��11�������Բ�����Ӧ����1����������Һ��ʼ30�����ڳ���ͷʹ����죬�Ķ����٣�������Һ�ٶȺ󻺽⡣Ѫ���п�����о�ǵ��׿���-3����Ѹ�ٽ��ͣ�1�����½�54%��2�����½�70%��3�����½�78%��������о�ǵ��׿���-3�����½�����IgGˮƽ���䡣���� ���������򵰰׿�Ѹ�ٿ��ƶ�������Ѱ�������崯���飬������Ӧ�����������ԣ����������Ƶ���Ч����֮һ��

�ؼ����� ���������崯;���������򵰰׳������;������о�ǵ��׿���-3  

Efficacy of intravenous immunoglobulin therapy in the treatment of refractory pemphigus vulgaris

Abstract:

Objective To evaluate the efficacy of intravenous immunoglobulin ��IVIg) in the treatment of refractory pemphigus vulgaris ��PV). Methods This study included 12 patients who were diagnosed as active PV by clinical and pathological examination as well as direct and indirect immunofluorescent test. All patients had been treated with high dose of steroids for one month but little improvement was achieved. Besides prednisone, patients were given IVIg 400 mg/kg once a day for 5 consecutive days with a 23-day interval as a treatment course during which the application of azathioprim or cyclophosphamide was stopped. The serum levels of antibodies to desmoglein 3 were detected by ELISA kits. The effects of IVIg were evaluated by the response of patients and required doses of prednisone. Side effects were also observed in this patients. Results Remission was achieved in 10 (83%) of the 12 patients one week after the treatment wtih IVIg. The dosage of prednisone declined by 30% 4 weeks later. Severe side effects were observed in none but 1 patient, who developed headache, flushing and tachycardia 30 minutes after the intravenous injection of immunoglobulin, whereas all symptoms were relieved after modulation of injection speed. Following the treatment, serum levels of antibodies to desmoglein 3 were rapidly decreased by 54% in week 1, 70% in week 2, 78% in week 3, while the level of IgG remained unchanged. Conclusions IVIg treatment combined with prednisone could rapidly control severe PV resistant to conventional therapies. Therefore, it may serve as an ideal adjuvant treatment of PV. ��Key words�� Pemphigus�� Infusions,intravenous�� Immunoglobulins

Keywords: therapy-resistant pemphigus vulgaris;Intravenous immunoglobulin;antibody to desmoglein 3  
�ո����� 2007-10-15 �޻����� 1900-01-01 ����淢������  
DOI:
������Ŀ:

ͨѶ����: ������
���߼��:

�ο����ף�
�������������

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־